Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the class period from June 16, 2025, to January 8, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Aquestive Therapeutics securities during the specified class period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding the approval timeline and launch of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film [3]. - Specific allegations include overstating the approval timeline, lacking a reasonable basis for confidence in the NDA submission, and concealing significant risks related to human factors associated with the product [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit have until May 4, 2026, to request appointment as lead plaintiff, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Fourth Quarter and Full Year 2025 Earnings Supplemental Materials September 2024 March 4, 2026 Solving problems. Improving lives. Advancing medicines. Disclaimer Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking stat ...